# Alemtuzumab in Treating Patients With Advanced Chronic Lymphocytic Leukemia That Did Not Respond to Previous Fludarabine

> **NCT00274976** · PHASE2 · COMPLETED · sponsor: **German CLL Study Group**

## Conditions studied

- Leukemia

## Interventions

- **BIOLOGICAL:** alemtuzumab

## Key facts

- **NCT ID:** NCT00274976
- **Lead sponsor:** German CLL Study Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** —
- **Final completion:** 2009-08
- **Target enrollment:** — (—)
- **Last updated:** 2013-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00274976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00274976, "Alemtuzumab in Treating Patients With Advanced Chronic Lymphocytic Leukemia That Did Not Respond to Previous Fludarabine". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00274976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*